MA33071B1 - Compose a noyau condenses et son utilisation - Google Patents
Compose a noyau condenses et son utilisationInfo
- Publication number
- MA33071B1 MA33071B1 MA34132A MA34132A MA33071B1 MA 33071 B1 MA33071 B1 MA 33071B1 MA 34132 A MA34132 A MA 34132A MA 34132 A MA34132 A MA 34132A MA 33071 B1 MA33071 B1 MA 33071B1
- Authority
- MA
- Morocco
- Prior art keywords
- nucleus
- intensive
- composite
- diseases
- angiotensin
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention porte sur un nouveau composé représenté par la formule suivante, dans laquelle chaque symbole est tel que défini dans la description, ou sur un sel de ce composé, qui a une activité antagoniste des récepteurs de l'angiotensine II et une activité agoniste du récepteur ³ activé par les proliférateurs des peroxysomes, et qui est utile en tant qu'agent pour la prophylaxie ou le traitement de maladies circulatoires, telles que l'hypertension et similaire, et/ou de maladies métaboliques, telles que le diabète et similaire, et similaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009020720 | 2009-01-30 | ||
| PCT/JP2010/051651 WO2010087515A1 (fr) | 2009-01-30 | 2010-01-29 | Composé à noyaux condensés et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33071B1 true MA33071B1 (fr) | 2012-02-01 |
Family
ID=42026435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34132A MA33071B1 (fr) | 2009-01-30 | 2010-01-29 | Compose a noyau condenses et son utilisation |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US8283353B2 (fr) |
| EP (1) | EP2384327B1 (fr) |
| JP (2) | JP4892649B1 (fr) |
| KR (1) | KR20110113758A (fr) |
| CN (2) | CN103788097B (fr) |
| AR (1) | AR075344A1 (fr) |
| AU (1) | AU2010208863A1 (fr) |
| CA (1) | CA2750710C (fr) |
| CL (1) | CL2011001848A1 (fr) |
| CO (1) | CO6362011A2 (fr) |
| CR (1) | CR20110463A (fr) |
| CY (1) | CY1114530T1 (fr) |
| DK (1) | DK2384327T3 (fr) |
| DO (1) | DOP2011000249A (fr) |
| EA (1) | EA019823B1 (fr) |
| EC (1) | ECSP11011294A (fr) |
| ES (1) | ES2433225T3 (fr) |
| GE (1) | GEP20135961B (fr) |
| HR (1) | HRP20131017T1 (fr) |
| IL (1) | IL214283A0 (fr) |
| MA (1) | MA33071B1 (fr) |
| ME (1) | ME01621B (fr) |
| MX (1) | MX2011008058A (fr) |
| MY (1) | MY152946A (fr) |
| NZ (1) | NZ594606A (fr) |
| PE (1) | PE20120593A1 (fr) |
| PL (1) | PL2384327T3 (fr) |
| PT (1) | PT2384327E (fr) |
| RS (1) | RS53012B (fr) |
| SG (1) | SG173135A1 (fr) |
| SI (1) | SI2384327T1 (fr) |
| TN (1) | TN2011000368A1 (fr) |
| TW (2) | TW201444848A (fr) |
| UY (1) | UY32409A (fr) |
| WO (1) | WO2010087515A1 (fr) |
| ZA (1) | ZA201105867B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2433225T3 (es) * | 2009-01-30 | 2013-12-10 | Takeda Pharmaceutical Company Limited | Compuesto con anillos condensados y uso del mismo |
| PT2655375E (pt) | 2010-12-23 | 2015-03-02 | Sanofi Sa | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica |
| CZ304252B6 (cs) * | 2011-04-11 | 2014-01-29 | Zentiva, K. S. | Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| WO2018165108A1 (fr) | 2017-03-08 | 2018-09-13 | Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals | Utilisation intradialytique de thiosulfate de sodium |
| WO2019067560A1 (fr) | 2017-09-26 | 2019-04-04 | Ecolab Usa Inc. | Compositions antimicrobiennes et virocides acides/anioniques et leurs utilisations |
| BR112020024269A2 (pt) | 2018-05-31 | 2021-02-23 | Hua Medicine (Shanghai) Ltd. | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (fr) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2 |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223558A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Composés aminés tricycliques en tant qu'inhibiteurs de cdk2 |
| WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
| WO2021030537A1 (fr) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2 |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| CN112745319B (zh) * | 2019-10-30 | 2022-06-17 | 中国科学院上海药物研究所 | 一类取代三环结构的化合物、其制备方法及用途 |
| AU2020408331B2 (en) | 2019-12-16 | 2023-12-14 | Ecolab Usa Inc. | Anionic surfactant impact on virucidal efficacy |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| EP4384167A1 (fr) * | 2021-08-13 | 2024-06-19 | Mpc Therapeutics Sa | [1,2,4] triazolo [4,3-a] pyrimidin -7 (8h)-one en tant qu'inhibiteurs de transporteur de pyruvate mitochondrial pour une utilisation dans le traitement du cancer |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472967A (en) | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
| FR2672892B1 (fr) * | 1991-02-20 | 1994-01-14 | Synthelabo | Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique. |
| TW251288B (fr) * | 1991-06-27 | 1995-07-11 | Takeda Dharm Industry Co Ltd | |
| IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
| IT1250749B (it) * | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | Composti eterociclici ad attivita' a ii antagonista |
| US5387747A (en) * | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
| FR2687677B1 (fr) * | 1992-02-24 | 1996-10-11 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5389632A (en) * | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| IT1263804B (it) | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
| GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| AU6158096A (en) | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure |
| AU5982296A (en) | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone |
| AU6039296A (en) * | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist |
| CN1142793C (zh) | 1995-06-07 | 2004-03-24 | G·D·瑟尔公司 | 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| SE0101579D0 (sv) | 2001-05-04 | 2001-05-04 | Astrazeneca Ab | New compounds |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| WO2005020984A2 (fr) | 2003-08-29 | 2005-03-10 | Aaipharma Inc. | Methode de reduction du stress oxydatif |
| WO2005074603A2 (fr) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Utilisation d'aminobenzoxazoles comme agents therapeutiques |
| MEP8409A (en) * | 2004-06-02 | 2011-12-20 | Fused heterocyclic compound | |
| WO2006000564A1 (fr) | 2004-06-23 | 2006-01-05 | Solvay Pharmaceuticals Gmbh | Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at1 |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| EP1937254A2 (fr) | 2005-07-27 | 2008-07-02 | Mor Research Applications Ltd. | Inhibition du systeme renine-angiotensine pour le traitement de pathologies renales, vasculaires et cartilagineuses |
| WO2007053406A1 (fr) | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinaison de composes organiques hypotenseurs et hypocholesterolemiant |
| WO2007051007A2 (fr) | 2005-10-28 | 2007-05-03 | Novartis Ag | Combinaison de composes organiques |
| US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| AU2007319505A1 (en) | 2006-11-09 | 2008-05-22 | Ore Pharmaceuticals Inc. | Breast cancer screening and treatment methods |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| EA200970510A1 (ru) * | 2006-11-24 | 2009-12-30 | Такеда Фармасьютикал Компани Лимитед | Гетеромоноциклическое соединение и его применение |
| EP2151440A4 (fr) | 2007-05-21 | 2010-10-20 | Takeda Pharmaceutical | Composé hétérocyclique et son utilisation |
| US20100221340A1 (en) | 2007-09-20 | 2010-09-02 | University Of Rochester | Method and compositions for treatment or prevention of inflammatory conditions |
| ES2524259T3 (es) | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
| EP2279009A4 (fr) | 2008-05-05 | 2011-09-21 | Univ Rochester | Procédés et compositions pour le traitement ou la prévention d'une remodélisation cardiaque pathologique et d'une insuffisance cardiaque |
| ES2433225T3 (es) | 2009-01-30 | 2013-12-10 | Takeda Pharmaceutical Company Limited | Compuesto con anillos condensados y uso del mismo |
-
2010
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
- 2010-01-29 RS RS20130472A patent/RS53012B/sr unknown
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/fr active Active
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Withdrawn
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
- 2010-01-29 HR HRP20131017AT patent/HRP20131017T1/hr unknown
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/fr not_active Ceased
- 2010-01-29 CA CA2750710A patent/CA2750710C/fr not_active Expired - Fee Related
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
-
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
-
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| MA30528B1 (fr) | Antagoniste du recepteur il-8. | |
| MA32614B1 (fr) | Compositions therapeutiques contenant du macitentan | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA31189B1 (fr) | Composés à cycles fusionnés utiles en tant qu'agonistes partiels de ppar-gamma | |
| MA46286B1 (fr) | Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1 | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| EA201390683A1 (ru) | Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp | |
| MA33840B1 (fr) | Nouveau composé de spiropipéridine | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| NO20074567L (no) | Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse | |
| MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
| MX2011011156A (es) | COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. | |
| EP2324029A4 (fr) | Inhibiteurs hétérocyliques des récepteurs de l'histamine destinés au traitement d'une maladie | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| MA33304B1 (fr) | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| MA33428B1 (fr) | Agonistes du gpr119 | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| TNSN08337A1 (fr) | Piperidinoylpyrrolidines agonistes du recepteur de melanocortine de type 4 | |
| EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
| MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
| MA32904B1 (fr) | Composes de purine |